Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Combining Chemical Genetics and Cancer Immunotherapy

This article was originally published in Start Up

Executive Summary

Two years ago, a team at Stanford described a new "chemical genetics" technique--a more precise way to use small molecules to perturb gene products and living systems. Now they have published more data on the system. And of acute interest to drug developers, they have linked the work to therapeutic applications in cancer immunotherapy, showing the ability to regulate secreted proteins such as IL-2 and TNF.

You may also be interested in...



Teasing Out Mechanisms of Small-Molecule Kinase Inhibition

Even as kinases remain a popular target in oncology for industry, two recent papers show how much we have yet to learn about how to interfere with these molecules. These most recent laboratory studies help explain the confusing observation that the very act of inhibiting a kinase with a drug can also "prime" phosphorylation of that target, which in some cases can actually enhance tumor activity.

Amping Up Dendritic Cells

Researchers are looking for ways to better stimulate dendritic cells (DCs, the antigen presenting cells that initiate and control many aspects of the immune response) in the hopes of creating potent vaccines against tumors and infectious diseases. A recent paper highlights progress on the DC targeting front using a DNA vaccine strategy, but is also a reminder that the immunotherapy field has a long way to go.

A New Perspective on Cancer Immunotherapy

Many believe that for therapeutic cancer vaccines, a more flexible two-stage system of proof-of-principle trials followed by efficacy trials should replace the current Phase I-III structure. That's because the paradigm used for oncology drug development is based on criteria developed for cytotoxic agents, which present a very different toxicity profile, metabolism, and manner of biological and clinical response.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC091660

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel